FdaApplication
BLA 125477
Identifiers
- fda_app_no: BLA125477
Properties
| Property | Value |
|---|---|
| applicant_name | Eli Lilly and Company |
| application_type | BLA |
| approval_date | 2014-04-21 |
Revenue by product
CYRAMZA
| Period | Revenue |
|---|---|
| Q4 2024 | $258.5M |
| Q3 2024 | $236.0M |
| Q2 2024 | $248.9M |
| Q1 2024 | $229.9M |
| Q4 2023 | $253.6M |
| Q3 2023 | $224.1M |
| Q2 2023 | $260.3M |
| Q1 2023 | $236.8M |
| Q4 2022 | $277.8M |
| Q3 2022 | $232.1M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CYRAMZA | RAMUCIRUMAB | 500MG/50ML (10MG/ML) | Injection |
| CYRAMZA | RAMUCIRUMAB | 100MG/10ML (10MG/ML) | Injection |
2 products